All Articles

The payment tech firm posts record cash flow and raises guidance, but a closer look reveals a story of strategic acquisitions and uneven performance.

Gogo's Q2 results show a net loss, but a 40% surge in military revenue is funding its critical, costly transition to next-gen Galileo and 5G services.

A new government initiative is accelerating a massive Québec phosphate mine, revealing a strategy to secure vital resources for food and batteries.

A new federal grant is helping Frontier Lithium turn mining by-products into valuable fertilizer, a key step in building a greener North American battery supply chain.

With nearly $800M in cash, Immunovant is all-in on a single drug, IMVT-1402. Can its ambitious six-front clinical strategy justify the burn and win the race?

The Edinburgh International Festival bets big on America's 250th, leveraging cultural diplomacy and star power for a major economic and reputational payoff.

The Yankees partner with prediction market Polymarket, signaling a major shift in sports sponsorship, fan engagement, and regulated financial technology.

American Growth Insurance's acquisition of Heller-Kowitz isn't just another deal. It’s the first move in a high-stakes bet to rebuild Main Street agencies.

Fox Corp. posts record earnings fueled by the World Cup, but the real story is its massive $22B bet on Roku to conquer the future of television streaming.

With its acquisition of Global Ledger and the hire of Novo's co-founder, OpenFX is building a bank for the fintechs that traditional finance won't touch.

With a return to profitability and digital revenue soaring, Lee Enterprises' Q3 results reveal a potent mix of financial strategy and digital transformation.

A strategic hire at RegTech firm RiskExec reveals a new reality: AI is no longer just a tool, but a core strategy for navigating financial regulation.

GPGI's Q2 results show a tale of two subsidiaries. While fintech darling CompoSecure hits records, industrial giant Husky faces market drag. Can one system steer both?

Priovant's Phase 3 trial for brepocitinib in cutaneous sarcoidosis isn't just about one disease. It's a key move in Roivant's playbook to build a rare disease powerhouse.

A new partnership between Japan's Ono Pharma and US biotech Mediar aims to disrupt the massive fibro-inflammatory disease market by targeting the root cell of scarring.

While competitors embrace complex dynamic pricing, Wyndham Rewards secures top honors for its ninth year by sticking to a simple, high-value strategy.

Sotera Health posted stellar Q2 results and raised its 2026 outlook, but a closer look at the numbers reveals a company navigating complex EO litigation.

With $60M in new funding and veteran pharma execs on board, Vedanta Biosciences is set for the pivotal last leg of its Phase 3 trial for VE303.

Genius Sports raises its outlook on soaring revenue post-acquisition, but a deeper look reveals widening losses. Can its strategic bet on data and media pay off?

BKV Corp. is building a new energy model, using robust gas profits to fund an ambitious expansion into power generation and carbon capture technology.